Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...
FiercePharma7h
Amid large cost-cutting drive, Pfizer plans manufacturing layoffs in Ireland
No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...
Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says
Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...
sicklecellanemianews9h
Pfizer withdraws Oxbryta from global markets, cites safety concerns
Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
FiercePharma10h
Pfizer gins up £2.4B after unloading hundreds of millions of Haleon shares
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
Medscape1d
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...
RTE Online8h
Pfizer to cut up to 210 jobs at Irish facilities
Pharmaceutical firm Pfizer is to cut more jobs at its Irish manufacturing facilities, as part of a global cost-cutting ...